KNSA - Company ID 0001730430
The table below shows Kiniksa Pharmaceuticals, Ltd.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $50.20M | $22.32M | $3.99M | -$4.27M | -$36.85M | -$40.12M |
| Capital expenditure | $161.00K | $99.00K | $84.00K | $24.00K | - | $54.00K |
| Investing cash flow | -$31.92M | -$51.54M | $25.52M | -$37.92M | -$22.72M | $44.83M |
| Dividends paid | - | - | - | - |
Kiniksa Pharmaceuticals, Ltd. reported operating cash flow of $137.99M for fiscal year 2025. That is up 437.1% from $25.69M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$50.22M (FY 2017) to $137.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $6.07M | $2.77M | $3.61M | $90.00K | $423.00K | $1.11M |